TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Attention Training or SSRIs on Symptoms and Neural Activation in Social Anxiety

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* A signed consent form~* Men and women between the ages of 18 and 65.~* Meeting a current diagnosis of Social Anxiety Disorder (SP) according to the DSM-IV.~* SP as the primary diagnosis: In cases of co-morbidity, SP will be deemed as the most distressing and clinically significant condition among the co-morbid disorders.~* No current pharmaco-therapy.~Exclusion Criteria:~* A diagnosis of psychotic or bipolar disorders.~* A diagnosis of a neurological disorder (i.e., epilepsy, brain injury).~* Drug or alcohol abuse.~* Any current pharmacological treatment.~* Any current psychotherapeutic treatment.~* Change in treatment during the study.~* Poor judgment capacity (i.e., children under 18 and special populations).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Gaze Contingent Music Reward Therapy (Type: EXPERIMENTAL): Participants will receive gaze-contingent feedback according to their viewing patterns, over a course of 12 weeks.
- Selective Serotonin Reuptake Inhibitors (Type: ACTIVE_COMPARATOR): Participants will receive 10-20 mg of Escitalopram over a course of 12 weeks.
- Waitlist Control (Type: PLACEBO_COMPARATOR): Participants will wait for treatment for 12 weeks, then receive GC-MRT for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 12-Week Study of Plecanatide for CIC (The National CIC3 Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female aged 18-80, inclusive~* Meets modified Rome III criteria for functional chronic idiopathic constipation for at least 3 months with symptom onset for at least 6 months~* Completed a colonoscopy in accordance with American Gastroenterological Association (AGA) colon cancer screening guidelines (5 years), with no clinically significant findings~* Willing to maintain a stable diet during the study~Exclusion Criteria:~* Loose stool (mushy) or watery (Bristol score 6 or 7) stool in the absence of any laxative or prohibited medicine for \> 25% of Bowel Movements (BMs) during the 3 months prior to screening visit OR during the 14 day pre-treatment assessment~* Active peptic ulcer disease, diabetes or hypertension not adequately treated or not stable~* History of cathartic colon, laxative, enema abuse, or ischemic colitis~* Fecal impaction within 3 months of screening~* Patient has had /has any: diseases or conditions associated with constipation (GI or CNS), structural abnormality of the GI tract or gastric bypass surgery, pelvic floor dysfunction, pseudo-obstruction, active infectious gastritis, diverticulitis, anal fissures or any disease or condition that can affect GI motility or defecation or can be associated with abdominal pain~* Unexplained and clinically significant alarm symptoms including lower GI bleeding, iron-deficiency anemia, weight loss or systemic signs of infection or colitis~* Major surgery, stroke or myocardial infarction (MI) within 60 days of screening~* Participated in a previous plecanatide clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Plecanatide 3.0 mg (Type: EXPERIMENTAL): Plecanatide tablets 3.0 mg QD for 12 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo tablets QD for 12 weeks
- Plecanatide 6.0 mg (Type: EXPERIMENTAL): Plecanatide tablets 6.0 mg QD for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Abatacept Versus Placebo to Assess the Prevention of Rheumatoid Arthritis (RA) in Adult Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of undifferentiated arthritis~* Clinical synovitis of two or more joints~* At least one but not more than three of the criteria for diagnosis of RA (1987).~* No prior disease modifying anti-rheumatic drugs (DMARDs)/biologics.~* Duration of disease must be 18 months or less.~* Positive for antibodies against cyclic citrullinated peptides.~Exclusion Criteria:~* Women of child bearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy.~* Active vasculitis of a major organ system.~* Severe or recurrent bacterial infection.~* History of cancer in the last five years except certain skin cancers.~* Herpes zoster that resolved less than 2 months prior to enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study on Once Daily FTC, ddI, Efavirenz Combination in Antiretroviral Naive HIV Infected Adults

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* HIV infection~* Antiretroviral naive~* CD4 cell count over 100/mm3~* Plasma HIV RNA load over 5,000 copies/mL~* Signed written informed consent~Exclusion Criteria:~* Hepatitis B infection~* Pregnancy~* Alcool abuse~* Acute infection, past neurological or pancreatic disease, biological abnormalities~* Chemotherapy or immunotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of BOTOX® Compared to Topiramate for the Prevention of Chronic Migraine in Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* History of chronic migraine~* More than 15 headache days in a 28 day period (headaches that last more than 4 hours and/or require treatment with prescription medication).~Exclusion Criteria:~* Taking opioid-containing products for acute headache treatment more than 8 days during a 28-day period~* Previous treatment with botulinum toxin of any serotype for any reason~* Previous treatment with topiramate~* On a ketogenic diet (high in fat, low in carbohydrates)~* History of acute myopia or increased intraocular pressure~* Diagnosis of myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis or any other significant disease that might interfere with neuromuscular function~* Acupuncture, transcutaneous electrical stimulation (TENS), cranial traction, dental splints for headache, or injection of anesthetics/steroids in the 4 weeks prior to screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- BOTOX® (Type: ACTIVE_COMPARATOR): 155U onabotulinumtoxinA (BOTOX®) total dose per treatment by intramuscular injection every 12 weeks for up to 3 treatments.
- Topiramate (Type: ACTIVE_COMPARATOR): Topiramate starting at a daily oral dose of 25 mg/day titrated up to a maximum dose of 100 mg/day for 36 weeks. Participants who discontinue topiramate are eligible to receive treatment with BOTOX®.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Transplantation of Astrocytes Derived From Human Embryonic Stem Cells, in Patients With Amyotrophic Lateral Sclerosis (ALS)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Main Inclusion Criteria:~1. El Escorial criteria for probable or definite ALS~2. Males and and non pregnant females between 18 and 70 years of age~3. Patients with an ALS-FRS-R score of at least 30 with an ALS diagnosis of two years or less~4. No history of active psychiatric disorder. Patients receiving antidepressants as a preventive treatment, with no history of active psychiatric disorder may be included.~5. Patient has a good understanding of the study and nature of the procedure~6. Patient provides written informed consent prior to any study procedure~7. Patients should either be on a stable dose of Riluzole and/or Radicava® (if applicable) for at least 30 days, or not be treated with Riluzole and/or Radicava®~8. Patient is medically able to tolerate immunosuppression regimen~9. Presence of a willing and able caregiver who understands the need to attend all follow-up visits, even if mobility declines~Main Exclusion Criteria:~1. Patient has a past infection or a positive test for HBV,HCV or HIV~2. Patient is in need of respiratory support~3. Patient has a lower than 10/12 in ALS-FRS-R respiratory parameters or below 70% of predicted slow vital capacity (SVC)~4. Patient has renal failure~5. Patient has impaired hepatic function~6. Patient has a Body Mass Index (BMI) of \<18.5 or \> 30~7. Patient suffers from significant cardiac disease, diabetes, autoimmune diseases, chronic severe infection, malignant disease or any other disease or condition that may risk the patient or interfere with the ability to interpret the study results~8. Patient has systemic inflammation or active infections~9. Patient has been treated previously with any stem cell therapy~10. Current use of immunosuppressant medication or use of such medication within 6 weeks of Screening visit (Visit 0)~11. Patient has participated in another clinical treatment trial or received other experimental medications outside of a clinical trial within 1 month prior to start of this study~12. Any known immunodeficiency syndrome~13. Any concomitant disease or condition limiting patient safety to participate

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- AstroRx (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Chronotherapy in Inflammatory Bowel Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Above the ages of 18~* Diagnosis of Crohn's Disease or Ulcerative Colitis~* Currently taking azathioprine or 6-mercaptopurine~* Willing to sign study consent form~Exclusion Criteria:~* Vulnerable population (pregnant, prisoner, non-English speaking or cognitively impaired)~* Breastfeeding subject~* Have a history of complications related to immunomodulatory therapy~* Participating in other research studies involving research interventions~* Treated with dual corticosteroid and immunomodulatory therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Morning (Type: EXPERIMENTAL): Participants with Ulcerative Colitis or Crohn's Disease taking 6-Mercatopurine or Azathioprine orally once a day in the evening were assigned to the morning group. Instead of taking their medication at their usual PM time, they were instructed to take their medications in the morning for the duration of the study-10 weeks. The dosage amount is per clinical care and not defined by the study protocol.
- Evening (Type: EXPERIMENTAL): Participants with Ulcerative Colitis or Crohn's Disease taking 6-Mercatopurine or Azathioprine orally once a day in the morning were assigned to the evening group. Instead of taking their medication at their usual AM time, they were instructed to take their medications in the evening for the duration of the study-10 weeks. The dosage amount is per clinical care and not defined by the study protocol.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must give a written, signed and dated informed consent~* Chronic plaque-type psoriasis present for at least 6 months before randomization~* Moderate to severe plaque psoriasis as defined at randomization by:~  * PASI score of ≥12 and~ * Body Surface Area (BSA) affected by plaque-type psoriasis ≥10% and~ * IGA mod 2011 ≥3 (based on a scale of 0-4)~* Candidate for systemic therapy, defined as having psoriasis inadequately controlled by:~  * Topical treatment (including topical corticosteroids) and/or~ * Phototherapy and/or~ * Previous systemic therapy~Exclusion Criteria:~* Forms of psoriasis other than plaque psoriasis~* Drug-induced psoriasis~* Ongoing use of prohibited treatments~* Previous exposure to secukinumab or any other biologic drug directly targeting IL-17A or IL-17RA, or ustekinumab, or any therapies targeting IL-12 or IL-23~* Use of any other investigational drugs within 5 half-lives of the investigational treatment before study drug initiation~* Pregnant or nursing (lactating) women~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Secukinumab (Type: EXPERIMENTAL): Secukinumab
- Ustekinumab (Type: ACTIVE_COMPARATOR): Ustekinumab

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patients willing to participate with confirmed diagnosis of COPD~* 40 years of age or older~* having a 10 pack year smoking history~* able to perform serial pulmonary function tests~* able to use both a DPI and Respimat device~Exclusion Criteria:~* Significant other disease~* clinically relevant abnormal hematology, chemistry, or urinalysis~* history of asthma~* diagnosis of thyrotoxicosis~* paroxysmal tachycardia related to beta agonists~* history of MI within 1 year, cardiac arrhythmia, hospitalization for heart failure within 1 year~* active tuberculosis, cystic fibrosis, clinically evident bronchiectasis~* significant alcohol or drug use~* pulmonary resection~* taking oral beta adrenergics~* taking unstable oral steroids~* daytime oxygen~* enrolled in rehabilitation program~* enrolled in another study or taking investigational products~* pregnant or nursing women, women of child bearing potential not willing to use two methods of birth control~* those who are not willing to comply with pulmonary medication washouts

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BI 1744 (Olodaterol) Low Dose (Type: EXPERIMENTAL): BI1744 Low Dose once daily
- BI 1744 (Olodaterol) Med Dose (Type: EXPERIMENTAL): BI 1744 Med Dose once daily
- Placebo (Type: PLACEBO_COMPARATOR): Placebo once daily
- Foradil (Type: ACTIVE_COMPARATOR): Foradil 12 mcg twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ferumoxytol Versus Oral Iron in the Treatment of Anemia in Hemodialysis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients ≥18 years.~* Chronic hemodialysis.~* Stable supplemental EPO therapy.~* Baseline hemoglobin of ≤ 11.5 g/dl.~Exclusion Criteria:~* Women who are pregnant or who are breast feeding.~* Received another investigational drug or device within 30 days.~* Recent parenteral or oral iron therapy.~* Patients with active GI bleeding or acute bleeding within 4 weeks. Patients that have other causes of anemia.~* Major surgery within 30 days or anticipated or planned surgery during the study.~* Patients with active infections.~* Recent blood transfusions.~* Patients with known allergies to iron products.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who have reached scheduled end of study in BENEFIT, either by developing CDMS or by completing 24 months~Exclusion Criteria:~* No participation in the initial BENEFIT study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 48 Years
- Healthy Volunteers: f

Study Arms:
- Initial IFNB-1b (Interferon beta-1b) (Type: EXPERIMENTAL): Initial Betaferon/Betaseron treatment (Interferon beta-1b, IFNB-1b), 250 ug administered s.c. (subcutaneous) every other day, continued in Follow-up phase
- Initial Placebo (Type: EXPERIMENTAL): Initial placebo treatment; Betaferon/Betaseron, 250 ug administered s.c. (subcutaneous) every other day offered in Follow-up phase (= this trial)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Renal Function Impairment on the Pharmacokinetics of LEE011

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria (All Subjects):~* Male or female (sterile or postmenopausal) subjects between 18-75 (both inclusive) years of age and healthy as determined by absence of clinically significant deviation from normal in medical history, physical examination, vital signs, electrocardiograms, and clinical laboratory determinations (except for renal impaired subjects).~* Subjects must have a BMI between 18 kg/m2 and 38 kg/m2 and weight at least 50 kg and no more than 120 kg.~* Additional inclusion criteria for subjects with normal renal function:~  * An absolute GFR as determined by MDRD equation and conversion within normal range as determined by GFR \> 90 mL/min~Inclusion Criteria (for subjects with impaired renal function):~- Subjects must have documented stable renal disease without evidence of renal progressive disease (stable renal disease is defined as no significant change, such as a stable absolute GFR, for 4 weeks prior to study entry.~Exclusion Criteria (All Subjects):~* Subject has received a renal transplant at any time in the past and is on immunosuppressant therapy~* History or presence of impaired cardiac function~* Any surgical or medical condition that may significantly alter the absorption, distribution, metabolism, or excretion of drugs~* Administration of CYP3A4/5 inhibitors or inducers or CYP3A4 substrates with narrow therapeutic windows~* Administration of medications that prolong the QT interval~* Subject has a history of immunodeficiency diseases, including HIV, as confirmed by (HIV-1, HIV-2) test~* Receipt of investigational product in another clinical trial within 4 weeks of dosing~Exclusion Criteria (for subjects with impaired renal function):~* Severe albuminuria \> 300 mg/day~* Subjects undergoing any method of dialysis~* Subjects with renal impairment due to hepatic disease (hepatorenal syndrome)~Other protocol-defined Inclusion/Exclusion may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Normal renal function (Type: EXPERIMENTAL): Normal renal function; matched demography to renal impariment cohorts
- Severe renal impairment (Type: EXPERIMENTAL): Severe decrease in GFR (15-29 ml/min)
- End Stage Renal Disease (Type: EXPERIMENTAL): End stage renal disease not on dialysis; GFR \<15 ml/min
- Mild renal impairment (Type: EXPERIMENTAL): Mild decrease in GFR (60-89 ml/min)
- Moderate renal impairment (Type: EXPERIMENTAL): Moderate decrease in GFR (30-59 ml/min)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete